FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136799> ?p ?o ?g. }

• W4324136799 endingPage "541" @default.
• W4324136799 startingPage "541" @default.
• W4324136799 abstract "541 Background: PURE-01 trial enrolled 155 patients who received 3 cycles of pembrolizumab (IO) every 3 weeks before radical cystectomy. We compared tumor-microenvironment immune markers expression in pre- and post-IO TURB specimens in complete/major and non-responders to identify features associated with pathologic response. Methods: We evaluated pre-IO TURB samples of 18 complete responders (CR: ypT0), 6 major responders (MR: ypTa/ypT1) and 19 non-responders (NR: ypT2/ypT3, N0 or N+) and post-IO specimen of 7 CR, 3 MR and 14 NR. Immunohistochemistry analysis for lymphocytes (CD3, CD8, CD20), macrophages (CD68, CD163), immune checkpoints (PD1, PD-L1) and HLA molecule (MHC-I, HLA-DR, B2M) was performed. A semiquantitative count was made on all samples by 3 expert pathologists and a quantitative whole-slide digital evaluation was performed using QuPath (v.0.3) to assess cell density (cells per mm 2 ) and expression of immune checkpoint and HLA molecules. Results: Semiquantitative count showed that seven markers (CD8, CD163, stromal or tumor PD-L1, HLA-DR and B2M on tumor cells) were significantly more expressed on TURB lesions from responders (CR + MR or CR only) compared to NR (N0 or N+) (p-value range: 0.001 to 0.048). In addition to such markers, patients achieving a CR, compared to NR, showed significantly higher expression of CD68 and CD163, of PD-1 on lymphocytes, as well as of tumor MHC-I molecules. Comparison of lesions from patients with CR vs MR revealed significant differences for CD3, CD163, PD-1 and MHC-I, all these markers being more frequently expressed on the former group compared to the latter. Digital pathology analysis confirmed this results on whole-slide evaluation showing higher density of CD8, CD163, PD-L1 and PD-1, and a higher expression B2M, MHC-I and HLA-DR (p-value range: 0.02 to 0.002) in responders. Moreover, N0 patients showed higher expression of PD-L1 and HLA-DR compared to N+ patients. Comparison of pre- and post-IO samples from NR patients showed an increased density of CD8 and CD20 cells (p-value: 0.04 and 0.01), and a decrease of CD163 and HLA-ABC (p-value: 0.003 and 0.02) expressing cells in the post-therapy samples. Conclusions: The tumor immune microenvironment of pre-therapy TURB lesions of patients achieving a complete or major pathologic response after neoadjuvant pembrolizumab shows significant enrichment for T cells and myeloid cells, for stromal or tumor PD-L1 as well as increased MHC-I expression on tumor cells compared to lesions from non responders. Post-IO surgical samples of NR patients showed downregulation of HLA-Class I antigens, in spite of increased CD8 and CD20 density. Clinical trial information: NCT02736266 ." @default.
• W4324136799 created "2023-03-15" @default.
• W4324136799 creator A5001956192 @default.
• W4324136799 creator A5005762669 @default.
• W4324136799 creator A5008187226 @default.
• W4324136799 creator A5016473783 @default.
• W4324136799 creator A5017108005 @default.
• W4324136799 creator A5017161374 @default.
• W4324136799 creator A5017608697 @default.
• W4324136799 creator A5039670785 @default.
• W4324136799 creator A5062688482 @default.
• W4324136799 creator A5067994961 @default.
• W4324136799 creator A5082906275 @default.
• W4324136799 creator A5083331837 @default.
• W4324136799 creator A5086507632 @default.
• W4324136799 creator A5090061046 @default.
• W4324136799 date "2023-02-20" @default.
• W4324136799 modified "2023-09-27" @default.
• W4324136799 title "Digital evaluation of tumor microenvironment immune markers pre- and post-neoadjuvant pembrolizumab in muscle-invasive bladder cancer (Pure-01 trial: An open label, single arm, phase II study)." @default.
• W4324136799 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.541" @default.
• W4324136799 hasPublicationYear "2023" @default.
• W4324136799 type Work @default.
• W4324136799 citedByCount "1" @default.
• W4324136799 countsByYear W43241367992023 @default.
• W4324136799 crossrefType "journal-article" @default.
• W4324136799 hasAuthorship W4324136799A5001956192 @default.
• W4324136799 hasAuthorship W4324136799A5005762669 @default.
• W4324136799 hasAuthorship W4324136799A5008187226 @default.
• W4324136799 hasAuthorship W4324136799A5016473783 @default.
• W4324136799 hasAuthorship W4324136799A5017108005 @default.
• W4324136799 hasAuthorship W4324136799A5017161374 @default.
• W4324136799 hasAuthorship W4324136799A5017608697 @default.
• W4324136799 hasAuthorship W4324136799A5039670785 @default.
• W4324136799 hasAuthorship W4324136799A5062688482 @default.
• W4324136799 hasAuthorship W4324136799A5067994961 @default.
• W4324136799 hasAuthorship W4324136799A5082906275 @default.
• W4324136799 hasAuthorship W4324136799A5083331837 @default.
• W4324136799 hasAuthorship W4324136799A5086507632 @default.
• W4324136799 hasAuthorship W4324136799A5090061046 @default.
• W4324136799 hasConcept C104317684 @default.
• W4324136799 hasConcept C114684123 @default.
• W4324136799 hasConcept C121608353 @default.
• W4324136799 hasConcept C126322002 @default.
• W4324136799 hasConcept C127716648 @default.
• W4324136799 hasConcept C142724271 @default.
• W4324136799 hasConcept C167672396 @default.
• W4324136799 hasConcept C18031839 @default.
• W4324136799 hasConcept C203014093 @default.
• W4324136799 hasConcept C204232928 @default.
• W4324136799 hasConcept C2775858924 @default.
• W4324136799 hasConcept C2776107976 @default.
• W4324136799 hasConcept C2776460901 @default.
• W4324136799 hasConcept C2777701055 @default.
• W4324136799 hasConcept C2778326572 @default.
• W4324136799 hasConcept C2780057760 @default.
• W4324136799 hasConcept C2780352672 @default.
• W4324136799 hasConcept C55493867 @default.
• W4324136799 hasConcept C71924100 @default.
• W4324136799 hasConcept C86803240 @default.
• W4324136799 hasConcept C8891405 @default.
• W4324136799 hasConceptScore W4324136799C104317684 @default.
• W4324136799 hasConceptScore W4324136799C114684123 @default.
• W4324136799 hasConceptScore W4324136799C121608353 @default.
• W4324136799 hasConceptScore W4324136799C126322002 @default.
• W4324136799 hasConceptScore W4324136799C127716648 @default.
• W4324136799 hasConceptScore W4324136799C142724271 @default.
• W4324136799 hasConceptScore W4324136799C167672396 @default.
• W4324136799 hasConceptScore W4324136799C18031839 @default.
• W4324136799 hasConceptScore W4324136799C203014093 @default.
• W4324136799 hasConceptScore W4324136799C204232928 @default.
• W4324136799 hasConceptScore W4324136799C2775858924 @default.
• W4324136799 hasConceptScore W4324136799C2776107976 @default.
• W4324136799 hasConceptScore W4324136799C2776460901 @default.
• W4324136799 hasConceptScore W4324136799C2777701055 @default.
• W4324136799 hasConceptScore W4324136799C2778326572 @default.
• W4324136799 hasConceptScore W4324136799C2780057760 @default.
• W4324136799 hasConceptScore W4324136799C2780352672 @default.
• W4324136799 hasConceptScore W4324136799C55493867 @default.
• W4324136799 hasConceptScore W4324136799C71924100 @default.
• W4324136799 hasConceptScore W4324136799C86803240 @default.
• W4324136799 hasConceptScore W4324136799C8891405 @default.
• W4324136799 hasIssue "6_suppl" @default.
• W4324136799 hasLocation W43241367991 @default.
• W4324136799 hasOpenAccess W4324136799 @default.
• W4324136799 hasPrimaryLocation W43241367991 @default.
• W4324136799 hasRelatedWork W2028907148 @default.
• W4324136799 hasRelatedWork W2061526284 @default.
• W4324136799 hasRelatedWork W2482010 @default.
• W4324136799 hasRelatedWork W2897425460 @default.
• W4324136799 hasRelatedWork W3099369776 @default.
• W4324136799 hasRelatedWork W3164563452 @default.
• W4324136799 hasRelatedWork W4229030863 @default.
• W4324136799 hasRelatedWork W4377103915 @default.
• W4324136799 hasRelatedWork W4380738087 @default.
• W4324136799 hasRelatedWork W2737989649 @default.
• W4324136799 hasVolume "41" @default.
• W4324136799 isParatext "false" @default.
• W4324136799 isRetracted "false" @default.

• next